应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
INCY 因塞特医疗
休市中 05-02 16:00:00 EDT
62.53
+0.50
+0.81%
盘后
59.41
-3.12
-4.99%
17:28 EDT
最高
62.87
最低
61.37
成交量
152.52万
今开
62.85
昨收
62.03
日振幅
2.42%
总市值
121.04亿
流通市值
100.93亿
总股本
1.94亿
成交额
9,504万
换手率
0.94%
流通股本
1.61亿
市净率
3.30
ROE
0.47%
每股收益
0.10
52周最高
83.95
52周最低
52.73
市盈率
644.47
股息
0.00
股息收益率
0.00
ROA
2.03%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
富国银行:维持Incyte(INCY.US)评级,由持股观望调整至持股观望评级, 目标价由58.00美元调整至59.00美元。
金融界 · 04-30 16:06
富国银行:维持Incyte(INCY.US)评级,由持股观望调整至持股观望评级, 目标价由58.00美元调整至59.00美元。
小摩:维持Incyte评级,由中性调整至中性评级, 目标价由70.00美元调整至68.00美元。
金融界 · 04-21
小摩:维持Incyte评级,由中性调整至中性评级, 目标价由70.00美元调整至68.00美元。
因塞特4月15日成交额为8680.10万美元
市场透视 · 04-16
因塞特4月15日成交额为8680.10万美元
因塞特4月14日成交额为1.23亿美元
市场透视 · 04-15
因塞特4月14日成交额为1.23亿美元
因塞特盘中异动 下午盘大幅跳水5.06%报69.78美元
市场透视 · 03-03
因塞特盘中异动 下午盘大幅跳水5.06%报69.78美元
因塞特2024财年实现净利润32.62百万美元,同比减少94.55%
市场透视 · 02-14
因塞特2024财年实现净利润32.62百万美元,同比减少94.55%
异动解读 | 因塞特医疗因2024年第四季度财报利润大幅失准,导致股价盘后大跌9.93%
异动解读 · 02-10
异动解读 | 因塞特医疗因2024年第四季度财报利润大幅失准,导致股价盘后大跌9.93%
异动解读 | 因塞特医疗2024年第四季度财报暗淡,销售额虽高但每股收益大幅失准,股价盘中大跌5.26%
异动解读 · 02-10
异动解读 | 因塞特医疗2024年第四季度财报暗淡,销售额虽高但每股收益大幅失准,股价盘中大跌5.26%
因塞特盘中异动 股价大跌5.29%
市场透视 · 02-10
因塞特盘中异动 股价大跌5.29%
Incyte公司预测2025年Jakafi收入为29.25亿至29.75亿美元,Opzelura销售额为6.30亿至6.70亿美元
财报速递 · 02-10
Incyte公司预测2025年Jakafi收入为29.25亿至29.75亿美元,Opzelura销售额为6.30亿至6.70亿美元
Incyte 2024年第四季度调整后每股收益为$1.43,低于预期的$1.56,销售额$11.8亿高于预期的$11.4亿
财报速递 · 02-10
Incyte 2024年第四季度调整后每股收益为$1.43,低于预期的$1.56,销售额$11.8亿高于预期的$11.4亿
特朗普2.0时代即将开启,投资机会如何掘金?
招商基金 · 01-20
特朗普2.0时代即将开启,投资机会如何掘金?
摩根大通证券公司:重申Incyte(INCY.US)评级,由大市一致调整至大市一致评级。
金融界 · 01-14
摩根大通证券公司:重申Incyte(INCY.US)评级,由大市一致调整至大市一致评级。
坎托菲茨杰拉德公司:重申Incyte(INCY.US)评级,由中性调整至中性评级。
金融界 · 01-10
坎托菲茨杰拉德公司:重申Incyte(INCY.US)评级,由中性调整至中性评级。
富国银行:维持Incyte评级
证券之星 · 2024-12-19
富国银行:维持Incyte评级
因塞特盘中异动 下午盘快速下挫5.04%报72.09美元
市场透视 · 2024-12-09
因塞特盘中异动 下午盘快速下挫5.04%报72.09美元
因塞特股价重挫12.29% 市值跌15.98亿美元
市场透视 · 2024-11-19
因塞特股价重挫12.29% 市值跌15.98亿美元
因塞特盘中异动 急速上涨5.16%报81.27美元
市场透视 · 2024-11-06
因塞特盘中异动 急速上涨5.16%报81.27美元
因塞特2024财年第三财季实现净利润1.06亿美元,同比减少38.01%
市场透视 · 2024-11-02
因塞特2024财年第三财季实现净利润1.06亿美元,同比减少38.01%
公司概况
公司名称:
因塞特医疗
所属市场:
NASDAQ
上市日期:
--
主营业务:
因塞特医疗公司于1991年在特拉华州注册成立。该公司是一家全球生物制药公司,致力于专有疗法的发现、开发和商业化。该公司专注于两个治疗领域,这两个领域由其获批药物的适应症和其临床候选药物正在开发的疾病定义。一个治疗领域是血液学/肿瘤学,包括骨髓增生性肿瘤(MPN)、移植物抗宿主病(GVHD)、实体瘤和血液系统恶性肿瘤。另一个治疗领域是炎症和自身免疫(IAI),包括其皮肤病学商业特许经营权。该公司还有权获得其发现并授权给第三方的分子的里程碑和特许权使用费。
发行价格:
--
{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":62.53,"timestamp":1746216000000,"preClose":62.03,"halted":0,"volume":1525246,"hourTrading":{"tag":"盘后","latestPrice":59.41,"preClose":62.53,"latestTime":"17:28 EDT","volume":47178,"amount":2949712.6,"timestamp":1746221294467},"delay":0,"floatShares":161408579,"shares":193569934,"eps":0.097025,"marketStatus":"休市中","change":0.5,"latestTime":"05-02 16:00:00 EDT","open":62.85,"high":62.8683,"low":61.365,"amount":95038098.08819799,"amplitude":0.024235,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.097025,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1746432000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":62.03,"preHourTrading":{"tag":"盘前","latestPrice":62.2,"preClose":62.03,"latestTime":"09:26 EDT","volume":722,"amount":45220.24624,"timestamp":1746192385184},"postHourTrading":{"tag":"盘后","latestPrice":59.41,"preClose":62.53,"latestTime":"17:28 EDT","volume":47178,"amount":2949712.6,"timestamp":1746221294467},"volumeRatio":0.6550228542345181,"impliedVol":0.3955,"impliedVolPercentile":0.552},"requestUrl":"/m/hq/s/INCY/wiki","defaultTab":"wiki","newsList":[{"id":"2532506866","title":"富国银行:维持Incyte(INCY.US)评级,由持股观望调整至持股观望评级, 目标价由58.00美元调整至59.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2532506866","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532506866?lang=zh_cn&edition=full","pubTime":"2025-05-01 00:06","pubTimestamp":1746029203,"startTime":"0","endTime":"0","summary":"富国银行:维持Incyte(INCY.US)评级,由持股观望调整至持股观望评级, 目标价由58.00美元调整至59.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/01000650063170.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INCY"],"gpt_icon":0},{"id":"2529333483","title":"小摩:维持Incyte评级,由中性调整至中性评级, 目标价由70.00美元调整至68.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529333483","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529333483?lang=zh_cn&edition=full","pubTime":"2025-04-22 01:21","pubTimestamp":1745256100,"startTime":"0","endTime":"0","summary":"小摩:维持Incyte(INCY.US)评级,由中性调整至中性评级, 目标价由70.00美元调整至68.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042201242794dd1717&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042201242794dd1717&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"2527193404","title":"因塞特4月15日成交额为8680.10万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527193404","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527193404?lang=zh_cn&edition=full","pubTime":"2025-04-16 09:39","pubTimestamp":1744767585,"startTime":"0","endTime":"0","summary":"美东时间2025年4月15日,因塞特成交额为8680.10万美元,成交额较昨日减少29.28%,当日成交量为147.97万股。因塞特于2025年4月15日跌1.28%,报58.46美元,该股过去5个交易日涨2.62%,年初至今跌15.36%,过去60日跌18.73%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-04-15|8680.10万|-29.28%|147.97万|#|2025-04-14|1.23亿|4.77%|208.92万|#|2025-04-11|1.17亿|-20.95%|207.37万|#|2025-04-10|1.48亿|-35.15%|267.86万|#|2025-04-09|2.29亿|38.79%|402.43万|Incyte专注于小分子药物的发现与研发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416093954a6bbe818&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416093954a6bbe818&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY","BK4139","BK4585","BK4550","BK4532","BK4588"],"gpt_icon":0},{"id":"2527086951","title":"因塞特4月14日成交额为1.23亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527086951","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527086951?lang=zh_cn&edition=full","pubTime":"2025-04-15 09:37","pubTimestamp":1744681069,"startTime":"0","endTime":"0","summary":"美东时间2025年4月14日,因塞特成交额为1.23亿美元,成交额较昨日增加4.77%,当日成交量为208.92万股。因塞特于2025年4月14日涨4.13%,报59.22美元,该股过去5个交易日跌1.77%,年初至今跌14.26%,过去60日跌18.28%。该公司首款皮肤科产品Opzelura于 2021 年获批用于治疗特应性皮炎,并于 2022 年获批用于治疗白癜风。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415093753a45921d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415093753a45921d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4139","INCY","BK4550","BK4588","BK4532"],"gpt_icon":0},{"id":"2516668460","title":"因塞特盘中异动 下午盘大幅跳水5.06%报69.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668460","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516668460?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:12","pubTimestamp":1741032745,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时12分,因塞特股票出现异动,股价急速下跌5.06%。截至发稿,该股报69.78美元/股,成交量137.436万股,换手率0.71%,振幅4.80%。因塞特股票所在的生物技术行业中,整体涨幅为0.06%。因塞特公司简介:Incyte专注于小分子药物的发现与研发。该公司首款皮肤科产品Opzelura于 2021 年获批用于治疗特应性皮炎,并于 2022 年获批用于治疗白癜风。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041225989a5b88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304041225989a5b88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","BK4550","INCY","BK4139","BK4532"],"gpt_icon":0},{"id":"2511692158","title":"因塞特2024财年实现净利润32.62百万美元,同比减少94.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511692158","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511692158?lang=zh_cn&edition=full","pubTime":"2025-02-15 00:00","pubTimestamp":1739548830,"startTime":"0","endTime":"0","summary":"2月15日,因塞特公布财报,公告显示公司2024财年净利润为32.62百万美元,同比减少94.55%;其中营业收入为42.41亿美元,同比增加14.75%,每股基本收益为0.16美元。从资产负债表来看,因塞特总负债20.35亿美元,其中短期债务10.00百万美元,资产负债比为2.70,流动比率为1.98。机构评级:截至2025年2月15日,当前有19家机构对因塞特目标价做出预测,其中目标均价为77.42美元,其中最低目标价为52.00美元,最高目标价为100.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000038a2461504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250215000038a2461504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"1157903796","title":"异动解读 | 因塞特医疗因2024年第四季度财报利润大幅失准,导致股价盘后大跌9.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157903796","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157903796?lang=zh_cn&edition=full","pubTime":"2025-02-11 06:58","pubTimestamp":1739228326,"startTime":"0","endTime":"0","summary":"北京时间2025年2月10日盘后,因塞特医疗股价大跌9.93%。引发这一剧烈波动的主因是该公司发布的2024年第四季度财报中,虽然销售额高于预期但关键利润指标每股收益却大幅低于分析师预期。具体来看,因塞特医疗当季每股收益为1.43美元,远低于分析师一致预期的1.56美元,差距高达8.33%。这一矛盾的现象或许意味着,公司在创收的同时未能有效控制相关成本,利润水平因此受到拖累。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INCY"],"gpt_icon":0},{"id":"1188418672","title":"异动解读 | 因塞特医疗2024年第四季度财报暗淡,销售额虽高但每股收益大幅失准,股价盘中大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1188418672","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188418672?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:36","pubTimestamp":1739198215,"startTime":"0","endTime":"0","summary":"因塞特医疗(INCY)今日盘中出现大幅波动,股价一度大跌5.26%,引发市场广泛关注。据了解,该公司2024年第四季度业绩虽然销售额高于预期,但关键利润指标每股收益却大幅低于预期。\n具体来看,因塞特医疗当季每股收益为1.43美元,低于分析师一致预期的1.56美元,差距高达8.33%。这一利润数据不佳,可能已引发市场对公司盈利前景的担忧。\n不过,公司当季销售额11.8亿美元,则高于分析师预期的11.4亿美元,增长了3.16%。尽管销售额表现出色,但利润的大幅失准,使得市场对公司在创收的同时控制成本方面的能力存疑。业内人士分析,公司未来业绩与资金使用效率将面临挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INCY"],"gpt_icon":0},{"id":"2510863202","title":"因塞特盘中异动 股价大跌5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510863202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510863202?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:34","pubTimestamp":1739198086,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时34分,因塞特股票出现异动,股价急速跳水5.29%。截至发稿,该股报70.21美元/股,成交量8.8876万股,换手率0.05%,振幅3.87%。因塞特股票所在的生物技术行业中,整体涨幅为0.35%。其相关个股中,Ocean Biomedical, Inc.、Nls Pharmaceutics Ltd.、Solid Biosciences Inc.涨幅较大,Nls Pharmaceutics Ltd.、Ocean Biomedical, Inc.、Conduit Pharmaceuticals Inc.较为活跃,换手率分别为937.28%、614.58%、259.05%,振幅较大的相关个股有Soligenix, Inc.、Tyra Biosciences, Inc.、Invivyd, Inc.,振幅分别为103.16%、100.83%、29.90%。因塞特公司简介:Incyte专注于小分子药物的发现和开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223446961e00d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223446961e00d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY","BK4585","BK4588","BK4532","BK4550","BK4139"],"gpt_icon":0},{"id":"1185456279","title":"Incyte公司预测2025年Jakafi收入为29.25亿至29.75亿美元,Opzelura销售额为6.30亿至6.70亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185456279","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185456279?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:17","pubTimestamp":1739189878,"startTime":"0","endTime":"0","summary":"Incyte公司预测2025年Jakafi收入为29.25亿至29.75亿美元,Opzelura销售额为6.30亿至6.70亿美元以上内容来自Benzinga Earnings专栏,原文如下:Incyte Forecasts 2025 Jakafi Revenue Of $2.925B-$2.975B And Opzelura Sales Of $630M-$670M","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"1141658251","title":"Incyte 2024年第四季度调整后每股收益为$1.43,低于预期的$1.56,销售额$11.8亿高于预期的$11.4亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1141658251","media":"财报速递","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141658251?lang=zh_cn&edition=full","pubTime":"2025-02-10 20:02","pubTimestamp":1739188979,"startTime":"0","endTime":"0","summary":"Incyte 报告其季度每股收益为$1.43,低于分析师一致预期的$1.56,差距为8.33%。公司报告其季度销售额为$11.8亿,高于分析师一致预期的$11.4亿,超出了3.16%。这一数字相比去年同期的$10.1亿增加了16.39%。以上内容来自Benzinga Earnings专栏,原文如下:Incyte reported quarterly earnings of $1.43 per share which missed the analyst consensus estimate of $1.56 by 8.33 percent. This is a 34.91 percent increase over earnings of $1.06 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.14 billion by 3.16 perc","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Incyte 2024年第四季度调整后每股收益为$1.43,低于预期的$1.56,销售额$11.8亿高于预期的$11.4亿","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启,投资机会如何掘金?","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启,有哪些投资机会可以布局?值得一提的是,科技股在特朗普任期内表现尤为突出,成为推动美股上涨的主要力量。在特朗普第一个任期内,美元整体表现相对弱势。4年任期内,美元指数累计下跌了10.53%。而纵观全球市场,在特朗普上一任期内,恒生科技指数涨幅超过147%,表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["STX","ALGN","ANSS","IDXX","ERIC","LIN","LOGI","KDP","LNT","MIDD","FRPT","EXE","ROP","MANH","WYNN","STLD","AMD","MARA","DASH","NVIW.SI","TPG","LKQ","CME","NTES","PAA","SEIC","BK4086","PCAR","CDNS","ALAB","INCY","INSM","MMYT","MRVL","ILMN","BK4561","INTC","CWST","NICE","SNPS","ROST","NQmain","ALNY","CASY","COKE","GILD","CSCO","ENTG","EVRG","GOOGL","LSCC","LU0757428866.USD","NBIX","NTNX","ZS","NXPI","HON","MCHP","HOLX","PAYX","NVMI","EXAS","RYAAY","TECH","CHRD","FOX","AMAT","JKHY","PEP","PTC","TLN","ONC","DDOG","GRAB","TTWO","TSCO","BK4581","BMRN","META","NVDA","RKLB","ORLY","ROIV","BIIB","FTNT","TTD","HBAN","NTRA","BKNG","MDB","LECO","GEN","PLTR","CBSH","DOCU","ARM","MDLZ","PARA","FCNCA","CPRT","SBAC","ITCI","PDD","ZM","AFRM","WBA","WTFC","AMZN","CHKP","CCEP","NWSA","EWBC","MKTX","Z","DUOL","FER","TQQQ","BPOP","NDSN","ARGX","GEHC","LAMR","BPMC","ON","RIVN","WWD","SIRI","SFM","AGNC","TSYW.SI","TXN","CPB","ASML","ISRG","REG","TSLA","DOX","CTAS","AAL","LU0053671581.USD","AKAM","MRNA","CSGP","ESLT","COO","CHTR","EQIX","CEG","KHC","JBHT","CHDN","PODD","FTAI","ADBE","MELI","HQY","GTLB","MNQmain","SWKS","ENPH","CSWI","HST","ADSK","PSQ","LULU","AAPL","CINF","FYBR","BK4593","PCTY","COST","FSV","AVGO","PCVX","ROKU","CZR","AUR","ERIE","SSNC","SRPT","CG","NFLX","OKTA","GMAB","NDAQ","PNFP","TER","TW","MNDY","POOL","HSIC","COIN","TMUS","LI","BK4585","MEDP","NTAP","DPZ","DLTR","AEP","BRKR","ADI","LU1815336091.USD","AMGN","BK4534","MSFT","QLD","BSY","HTHT","EA","QID","ODFL","HOOD","LNW","INTU","QCOM","CSX","REGN","LU2065731478.USD","PFG","QRVO","TEAM","RADX","USJW.SI","NTRS","RGLD","WDC","TCOM","OTEX","AAON","ICLR","GNTX","LSTR","DKNG","CFLT","GLPI","CHRW","DSGX","FFIV","MTCH","SBUX","SQQQ","TROW","FWONK","BKR","CRWD","MTSI","HLNE","TRMB","CYBR","QQQ","CDW","BK4550","MPWR","USAW.SI","EBAY","EXPE","QXO","SAIA","CTSH","AXON","RVMD","TTEK","RGEN","FSLR","LPLA","JD","RPRX",".IXIC","APA","SOFI","TSEM","ULTA","SMCI","FAST","MKSI","FOXA","OLED","BK4588","AZN","MNST"],"gpt_icon":1},{"id":"2503571851","title":"摩根大通证券公司:重申Incyte(INCY.US)评级,由大市一致调整至大市一致评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503571851","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503571851?lang=zh_cn&edition=full","pubTime":"2025-01-14 22:31","pubTimestamp":1736865081,"startTime":"0","endTime":"0","summary":"摩根大通证券公司:重申Incyte(INCY.US)评级,由大市一致调整至大市一致评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/14223147457602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["399975","159848","INCY"],"gpt_icon":0},{"id":"2502897710","title":"坎托菲茨杰拉德公司:重申Incyte(INCY.US)评级,由中性调整至中性评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2502897710","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502897710?lang=zh_cn&edition=full","pubTime":"2025-01-11 01:24","pubTimestamp":1736529852,"startTime":"0","endTime":"0","summary":"坎托菲茨杰拉德公司:重申Incyte(INCY.US)评级,由中性调整至中性评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/11012447364835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["INCY"],"gpt_icon":0},{"id":"2492177381","title":"富国银行:维持Incyte评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2492177381","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492177381?lang=zh_cn&edition=full","pubTime":"2024-12-19 23:18","pubTimestamp":1734621486,"startTime":"0","endTime":"0","summary":"富国银行:维持INCYte(INCY.US)评级,由持股观望调整至持股观望评级,目标价由68.00美元调整至70.00美元。因塞特(INCY.US)公司简介:因塞特医疗公司是一家生物制药公司,从事专利疗法的发现、开发和商业化。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219232501a1fb6f8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219232501a1fb6f8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"2490706382","title":"因塞特盘中异动 下午盘快速下挫5.04%报72.09美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490706382","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490706382?lang=zh_cn&edition=full","pubTime":"2024-12-10 02:03","pubTimestamp":1733767413,"startTime":"0","endTime":"0","summary":"北京时间2024年12月10日02时03分,因塞特股票出现异动,股价快速下跌5.04%。截至发稿,该股报72.09美元/股,成交量58.6711万股,换手率0.30%,振幅5.08%。机构评级方面,在所有28家参与评级的机构中,46%的券商给予买入建议,50%的券商给予持有建议,4%的券商给予卖出建议。因塞特股票所在的生物技术行业中,整体涨幅为0.59%。该公司的第一个皮肤科产品 Opzelura 于 2021 年被批准用于特应性皮炎,2022 年被批准用于白斑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210020333ab6a711c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241210020333ab6a711c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","BK4585","BK4550","BK4588","BK4139","INCY"],"gpt_icon":0},{"id":"2484692598","title":"因塞特股价重挫12.29% 市值跌15.98亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484692598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484692598?lang=zh_cn&edition=full","pubTime":"2024-11-19 22:31","pubTimestamp":1732026666,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日22时31分,因塞特股票出现异动,股价急速跳水12.29%。截至发稿,该股报67.51美元/股,成交量15.3454万股,换手率0.08%,振幅1.81%。最近的财报数据显示,该股实现营业收入11.38亿美元,净利润1.06亿美元,每股收益0.55美元,毛利10.35亿美元,市盈率750.11倍。因塞特股票所在的生物技术行业中,整体跌幅为0.46%。因塞特公司简介:Incyte专注于小分子药物的发现和开发。该公司的第一个皮肤科产品 Opzelura 于 2021 年被批准用于特应性皮炎,2022 年被批准用于白斑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922310695be4a6a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922310695be4a6a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4550","BK4532","INCY","BK4588","BK4139"],"gpt_icon":0},{"id":"2481598531","title":"因塞特盘中异动 急速上涨5.16%报81.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481598531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481598531?lang=zh_cn&edition=full","pubTime":"2024-11-06 22:38","pubTimestamp":1730903913,"startTime":"0","endTime":"0","summary":"北京时间2024年11月06日22时38分,因塞特股票出现波动,股价大幅拉升5.16%。截至发稿,该股报81.27美元/股,成交量47.6883万股,换手率0.25%,振幅3.60%。最近的财报数据显示,该股实现营业收入11.38亿美元,净利润1.06亿美元,每股收益0.55美元,毛利10.35亿美元,市盈率895.56倍。因塞特股票所在的生物技术行业中,整体跌幅为0.23%。因塞特公司简介:Incyte专注于小分子药物的发现和开发。该公司的第一个皮肤科产品 Opzelura 于 2021 年被批准用于特应性皮炎,2022 年被批准用于白斑病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223833971a4c74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241106223833971a4c74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY","BK4532","BK4550","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"2480487589","title":"因塞特2024财年第三财季实现净利润1.06亿美元,同比减少38.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480487589","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480487589?lang=zh_cn&edition=full","pubTime":"2024-11-03 00:00","pubTimestamp":1730563240,"startTime":"0","endTime":"0","summary":"11月3日,因塞特公布财报,公告显示公司2024财年第三财季净利润为1.06亿美元,同比减少38.01%;其中营业收入为11.38亿美元,同比增加23.83%,每股基本收益为0.55美元。从资产负债表来看,因塞特总负债18.41亿美元,其中短期债务8.28百万美元,资产负债比为2.73,流动比率为1.88。机构评级:截至2024年11月3日,当前有20家机构对因塞特目标价做出预测,其中目标均价为77.45美元,其中最低目标价为52.00美元,最高目标价为97.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000051a20f7aba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241103000051a20f7aba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com","stockEarnings":[{"period":"1week","weight":0.057},{"period":"1month","weight":0.0032},{"period":"3month","weight":-0.1568},{"period":"6month","weight":-0.1786},{"period":"1year","weight":0.1778},{"period":"ytd","weight":-0.0947}],"compareEarnings":[{"period":"1week","weight":0.0293},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0583},{"period":"6month","weight":-0.0075},{"period":"1year","weight":0.1222},{"period":"ytd","weight":-0.033}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。该公司是一家全球生物制药公司,致力于专有疗法的发现、开发和商业化。该公司专注于两个治疗领域,这两个领域由其获批药物的适应症和其临床候选药物正在开发的疾病定义。一个治疗领域是血液学/肿瘤学,包括骨髓增生性肿瘤(MPN)、移植物抗宿主病(GVHD)、实体瘤和血液系统恶性肿瘤。另一个治疗领域是炎症和自身免疫(IAI),包括其皮肤病学商业特许经营权。该公司还有权获得其发现并授权给第三方的分子的里程碑和特许权使用费。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.086406},{"month":2,"riseRate":0.3125,"avgChangeRate":-0.001863},{"month":3,"riseRate":0.4375,"avgChangeRate":-0.038633},{"month":4,"riseRate":0.46875,"avgChangeRate":-0.011198},{"month":5,"riseRate":0.59375,"avgChangeRate":0.060592},{"month":6,"riseRate":0.580645,"avgChangeRate":0.023436},{"month":7,"riseRate":0.516129,"avgChangeRate":0.013155},{"month":8,"riseRate":0.516129,"avgChangeRate":0.015671},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.020225},{"month":10,"riseRate":0.516129,"avgChangeRate":0.02439},{"month":11,"riseRate":0.580645,"avgChangeRate":0.059578},{"month":12,"riseRate":0.612903,"avgChangeRate":0.098493}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}